Browse by Audience
Skip to content
Papers of the Week
Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database.
Authors
Liu WH, Hu HM, Li C, Shi Q, Liu CH, Liu AX, Li YF, Zhang Y, Mao P, Fan BFAbstract
Triptans selectively agoniste 5-Hydroxytryptamine(5-HT) receptors and are widely used in the treatment of migraine. Nevertheless, there is a dearth of comprehensive real-world clinical research on the safety of triptans. In light of the growing prevalence of migraine, it is imperative to gain a deeper understanding of the true extent of adverse events (AEs) associated with triptans in the clinical management of migraine.